CA3120200A1 - Method of improving prediction of response for cancer patients treated with immunotherapy - Google Patents

Method of improving prediction of response for cancer patients treated with immunotherapy Download PDF

Info

Publication number
CA3120200A1
CA3120200A1 CA3120200A CA3120200A CA3120200A1 CA 3120200 A1 CA3120200 A1 CA 3120200A1 CA 3120200 A CA3120200 A CA 3120200A CA 3120200 A CA3120200 A CA 3120200A CA 3120200 A1 CA3120200 A1 CA 3120200A1
Authority
CA
Canada
Prior art keywords
loh
cancer
sample
tumor
tmb
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3120200A
Other languages
English (en)
French (fr)
Inventor
Nicholas C. Dracopoli
Gustavo CERQUEIRA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Personal Genome Diagnostics Inc
Original Assignee
Personal Genome Diagnostics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Personal Genome Diagnostics Inc filed Critical Personal Genome Diagnostics Inc
Publication of CA3120200A1 publication Critical patent/CA3120200A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CA3120200A 2018-11-15 2019-11-15 Method of improving prediction of response for cancer patients treated with immunotherapy Pending CA3120200A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862767979P 2018-11-15 2018-11-15
US62/767,979 2018-11-15
PCT/US2019/061710 WO2020102674A1 (en) 2018-11-15 2019-11-15 Method of improving prediction of response for cancer patients treated with immunotherapy

Publications (1)

Publication Number Publication Date
CA3120200A1 true CA3120200A1 (en) 2020-05-22

Family

ID=70727341

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3120200A Pending CA3120200A1 (en) 2018-11-15 2019-11-15 Method of improving prediction of response for cancer patients treated with immunotherapy

Country Status (6)

Country Link
US (2) US12497661B2 (https=)
EP (1) EP3880246A4 (https=)
JP (2) JP7623281B2 (https=)
AU (1) AU2019379167A1 (https=)
CA (1) CA3120200A1 (https=)
WO (1) WO2020102674A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230056761A (ko) * 2020-08-26 2023-04-27 리제너론 파마슈티칼스 인코포레이티드 Pd-1 저해제의 투여에 의한 암 치료 방법
CN111979323A (zh) * 2020-08-28 2020-11-24 深圳裕策生物科技有限公司 用于预测肿瘤免疫治疗效果的生物标志物检测方法及系统
CN112029861B (zh) * 2020-09-07 2021-09-21 臻悦生物科技江苏有限公司 基于捕获测序技术的肿瘤突变负荷检测装置及方法
WO2022232503A1 (en) * 2021-04-30 2022-11-03 Genentech, Inc. Therapeutic and diagnostic methods and compositions for cancer
WO2023196390A1 (en) * 2022-04-06 2023-10-12 Foundation Medicine, Inc. Aneuploidy biomarkers associated with response to anti-cancer therapies

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6531279B1 (en) * 1998-04-15 2003-03-11 Genset S.A. Genomic sequence of the 5-lipoxygenase-activating protein (FLAP), polymorphic markers thereof and methods for detection of asthma
US20030092019A1 (en) * 2001-01-09 2003-05-15 Millennium Pharmaceuticals, Inc. Methods and compositions for diagnosing and treating neuropsychiatric disorders such as schizophrenia
EP3012329B1 (en) * 2010-06-18 2017-10-25 Myriad Genetics, Inc. Methods and materials for assessing loss of heterozygosity
KR20230030022A (ko) * 2014-11-13 2023-03-03 더 존스 홉킨스 유니버시티 관문 차단 및 미소부수체 불안정성
MA40737A (fr) 2014-11-21 2017-07-04 Memorial Sloan Kettering Cancer Center Déterminants de la réponse d'un cancer à une immunothérapie par blocage de pd-1
CN117467603A (zh) 2015-04-27 2024-01-30 癌症研究技术有限公司 治疗癌症的方法
EP3323070B1 (en) 2015-07-14 2024-05-08 Personal Genome Diagnostics Inc. Neoantigen analysis
GB201516047D0 (en) 2015-09-10 2015-10-28 Cancer Rec Tech Ltd Method
CA3015913A1 (en) 2016-02-29 2017-09-08 Foundation Medicine, Inc. Methods of treating cancer
CN114959918A (zh) * 2016-02-29 2022-08-30 基础医疗股份有限公司 用于评估肿瘤突变负荷的方法和系统
JP6821693B2 (ja) * 2016-02-29 2021-01-27 ジェネンテック， インコーポレイテッド がんのための治療方法及び診断方法
US20190247435A1 (en) 2016-06-29 2019-08-15 The Johns Hopkins University Neoantigens as targets for immunotherapy
EP3516081A4 (en) 2016-09-23 2020-07-29 Memorial Sloan Kettering Cancer Center DETERMINANTS OF CANCER RESPONSE TO IMMUNOTHERAPY
WO2018071796A2 (en) 2016-10-13 2018-04-19 The Johns Hopkins University Compositions and methods for identifying functional anti-tumor t cell responses
US11634777B2 (en) * 2017-01-13 2023-04-25 The General Hospital Corporation Resistance to checkpoint blockade therapy
EP3601355A1 (en) 2017-03-31 2020-02-05 Bristol-Myers Squibb Company Methods of treating tumor
CN117987553A (zh) * 2017-09-25 2024-05-07 纪念斯隆凯特琳癌症中心 肿瘤突变负荷和检查点免疫疗法

Also Published As

Publication number Publication date
WO2020102674A1 (en) 2020-05-22
US20200157642A1 (en) 2020-05-21
JP2022513068A (ja) 2022-02-07
EP3880246A4 (en) 2022-08-10
EP3880246A1 (en) 2021-09-22
JP7623281B2 (ja) 2025-01-28
AU2019379167A1 (en) 2021-06-03
US12497661B2 (en) 2025-12-16
JP2025000809A (ja) 2025-01-07
US20260071282A1 (en) 2026-03-12

Similar Documents

Publication Publication Date Title
US20260071282A1 (en) Method of improving prediction of response for cancer patients treated with immunotherapy
Dushyanthen et al. Agonist immunotherapy restores T cell function following MEK inhibition improving efficacy in breast cancer
Rodríguez HLA‑mediated tumor escape mechanisms that may impair immunotherapy clinical outcomes via T‑cell activation
Biran et al. The genetics of alopecia areata: new approaches, new findings, new treatments
AU2019346023B2 (en) Method for selecting neoepitopes
Queirolo et al. Association of CTLA-4 polymorphisms with improved overall survival in melanoma patients treated with CTLA-4 blockade: a pilot study
Pagadala et al. Germline modifiers of the tumor immune microenvironment implicate drivers of cancer risk and immunotherapy response
Klaver et al. Differential quantities of immune checkpoint-expressing CD8 T cells in soft tissue sarcoma subtypes
Frijlink et al. PD-1 or CTLA-4 blockade promotes CD86-driven Treg responses upon radiotherapy of lymphocyte-depleted cancer in mice
WO2020221783A1 (en) Methods for pre-selection of neoepitopes
Malheiros et al. Genome‐wide gene expression profiling reveals unsuspected molecular alterations in pemphigus foliaceus
JP2025019066A (ja) 癌の免疫療法のための複合バイオマーカー
Castro et al. Neoantigen controversies
Li et al. Integrated genomic characterization of the human immunome in cancer
López‐Villalobos et al. Association of CD 28 and CTLA 4 haplotypes with susceptibility to primary Sjögren′ s syndrome in Mexican population
Luo et al. Positive association of major histocompatibility complex class I chain‐related gene A polymorphism with leukemia susceptibility in the people of Han nationality of Southern China
Gong et al. Clustering by antigen-presenting genes reveals immune landscapes and predicts response to checkpoint immunotherapy
Dahl et al. The pioneers behind immune checkpoint blockers awarded the Nobel Prize in physiology or medicine 2018
Hou et al. Rational discovery of response biomarkers: candidate prognostic factors and biomarkers for checkpoint inhibitor-based immunotherapy
Zhong et al. The necessary role of an efficient tumor immunotherapy by MHC II expression on amateur APCs
JP7626777B2 (ja) マイクロサテライト不安定性シグネチャー
RU2826184C2 (ru) Способ отбора неоэпитопов
Yan et al. Causal Impact of Immune Phenotypes on Herpes Zoster and Postherpetic Neuralgia: Insights from Mendelian Randomization Analysis
Goli et al. Human Leukocyte Antigen Determinants in Myocarditis and Dilated Cardiomyopathy
Soria et al. IL-6 and IL-27 negatively regulate CRTAM-expressing CD4+ T-cells associated with lymphoid-driven synovitis

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20230911

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD

Year of fee payment: 5

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241023

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241023

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241023

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20250116

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20250515

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250516

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250722

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250722

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - STANDARD

Year of fee payment: 6

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20251107

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20251107